Morpholino

MO1-spint1a

ID
ZDB-MRPHLNO-071218-5
Name
MO1-spint1a
Previous Names
None
Target
Sequence
5' - ACCCTGAGTAGAGCCAGAGTCATCC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Genome Build: GRCz11Chromosome: 17
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-spint1a
Phenotype
Phenotype resulting from MO1-spint1a
Phenotype Fish Figures
chorion accumulation keratinocyte, abnormal WT + MO1-spint1a Fig. 3 with image from Carney et al., 2007
epidermal basal stratum cell protruding out of epidermis, abnormal WT + MO1-spint1a Fig. 5 from Armistead et al., 2020
epidermal basal stratum cell motility increased occurrence, abnormal cy34Tg + MO1-spint1a Fig. 4 with imageFig. 6 with image from Schepis et al., 2018
epidermal basal stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-spint1a Fig. 7Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion decreased process quality, abnormal la213Tg; mu271Tg + MO1-spint1a Fig. 4 with imageFig. 7Fig. 8 from Schepis et al., 2018
epidermal basal stratum cytoplasm ab2-cdh1 labeling mislocalised, abnormal cy34Tg + MO1-spint1a Fig. 5 with image from Schepis et al., 2018
epidermal basal stratum keratinocyte aggregated, abnormal WT + MO1-spint1a Fig. 3 with image from Carney et al., 2007
epidermal superficial stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-spint1a Fig. 6 with imageFig. 7Fig. 8 from Schepis et al., 2018
epidermis development disrupted, abnormal WT + MO1-spint1a Fig. 3 with image from Carney et al., 2007
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-spint1a Fig. 3 with imageFig. 7Fig. 8 from Schepis et al., 2018
integument cell aggregated, abnormal WT + MO1-spint1a Fig. 2 with image from Schepis et al., 2018
keratinocyte disorganized, abnormal WT + MO1-spint1a Fig. 5 with image from Carney et al., 2007
keratinocyte mislocalised, abnormal WT + MO1-spint1a Fig. 3 with image from Carney et al., 2007
peridermal cell protruding out of epidermis, abnormal WT + MO1-spint1a Fig. 5 from Armistead et al., 2020
whole organism mmp13a.1 expression increased amount, abnormal WT + MO1-spint1a Fig. 7 from Schepis et al., 2018
whole organism il1b expression increased amount, abnormal WT + MO1-spint1a Fig. 7 from Schepis et al., 2018
whole organism mmp9 expression increased amount, abnormal WT + MO1-spint1a Fig. 7 from Schepis et al., 2018
Phenotype of all Fish created by or utilizing MO1-spint1a
Phenotype Fish Conditions Figures
whole organism mmp9 expression amount, ameliorated AB + MO1-spint1a hypotonic, chemical treatment by environment: mannitol Fig 1 with image from Hatzold et al., 2023
epidermis potentially cancerous lesions amount, ameliorated AB + MO1-spint1a hypotonic, chemical treatment by environment: mannitol Fig 1 with image from Hatzold et al., 2023
whole organism mmp9 expression increased amount, abnormal AB + MO1-spint1a hypotonic Fig 1 with image from Hatzold et al., 2023
epidermis potentially cancerous lesions increased amount, abnormal AB + MO1-spint1a hypotonic Fig 1 with image from Hatzold et al., 2023
epidermal basal stratum cell protruding out of epidermis, abnormal WT + MO1-spint1a control Fig. 5 from Armistead et al., 2020
epidermis development disrupted, abnormal WT + MO1-spint1a standard conditions Fig. 3 with image from Carney et al., 2007
keratinocyte mislocalised, abnormal WT + MO1-spint1a standard conditions Fig. 3 with image from Carney et al., 2007
whole organism mmp13a.1 expression increased amount, abnormal WT + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
peridermal cell protruding out of epidermis, abnormal WT + MO1-spint1a control Fig. 5 from Armistead et al., 2020
whole organism mmp9 expression increased amount, abnormal WT + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
integument cell aggregated, abnormal WT + MO1-spint1a standard conditions Fig. 2 with image from Schepis et al., 2018
epidermal basal stratum keratinocyte aggregated, abnormal WT + MO1-spint1a standard conditions Fig. 3 with image from Carney et al., 2007
chorion accumulation keratinocyte, abnormal WT + MO1-spint1a standard conditions Fig. 3 with image from Carney et al., 2007
keratinocyte disorganized, abnormal WT + MO1-spint1a standard conditions Fig. 5 with image from Carney et al., 2007
whole organism il1b expression increased amount, abnormal WT + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy22Tg + MO1-spint1a standard conditions Fig. 3 with image from Schepis et al., 2018
epidermal basal stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-spint1a standard conditions Fig. 7Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated cy34Tg + MO1-spint1a chemical treatment: matrix metalloproteinase inhibitor Fig. 7 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-spint1a standard conditions Fig. 7Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, exacerbated cy34Tg + MO1-spint1a chemical treatment: matrix metalloproteinase inhibitor Fig. 7 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-spint1a standard conditions Fig. 6 with imageFig. 7Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell motility increased occurrence, abnormal cy34Tg + MO1-spint1a standard conditions Fig. 6 with image from Schepis et al., 2018
epidermal basal stratum cytoplasm ab2-cdh1 labeling mislocalised, abnormal cy34Tg + MO1-spint1a standard conditions Fig. 5 with image from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion process quality, ameliorated la213Tg; mu271Tg + MO1-spint1a chemical treatment: matrix metalloproteinase inhibitor Fig. 7 from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion process quality, ameliorated la213Tg; mu271Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell motility increased occurrence, abnormal la213Tg; mu271Tg + MO1-spint1a standard conditions Fig. 4 with image from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion decreased process quality, abnormal la213Tg; mu271Tg + MO1-spint1a standard conditions Fig. 4 with imageFig. 7Fig. 8 from Schepis et al., 2018
whole organism mmp13a.1 expression amount, ameliorated f2rl1.2sfc18b/sfc18b + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
integument cell aggregated, ameliorated f2rl1.2sfc18b/sfc18b + MO1-spint1a standard conditions Fig. 2 with image from Schepis et al., 2018
whole organism il1b expression amount, ameliorated f2rl1.2sfc18b/sfc18b + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
whole organism mmp9 expression amount, ameliorated f2rl1.2sfc18b/sfc18b + MO1-spint1a standard conditions Fig. 7 from Schepis et al., 2018
keratinocyte proliferation increased occurrence, abnormal spint1ahi2217Tg/hi2217Tg + MO1-spint1a + MO1-spint1b standard conditions Fig. 4 with image from Carney et al., 2007
integument cell aggregated, ameliorated WT + MO1-f2rl1.2 + MO1-spint1a standard conditions Fig. 2 with image from Schepis et al., 2018
chorion accumulation keratinocyte, abnormal WT + MO1-spint1a + MO1-spint1b standard conditions Fig. 3 with image from Carney et al., 2007
epidermal basal stratum keratinocyte aggregated, abnormal WT + MO1-spint1a + MO1-spint1b standard conditions Fig. 3 with image from Carney et al., 2007
keratinocyte mislocalised, abnormal WT + MO1-spint1a + MO1-spint1b standard conditions Fig. 3 with image from Carney et al., 2007
keratinocyte disorganized, abnormal WT + MO1-spint1a + MO1-spint1b standard conditions Fig. 5 with image from Carney et al., 2007
epidermis development disrupted, abnormal WT + MO1-spint1a + MO1-spint1b standard conditions Fig. 3 with image from Carney et al., 2007
integument cell aggregated, ameliorated WT + MO1-spint1a + MO1-st14a standard conditions Fig. 2 with image from Schepis et al., 2018
whole organism mmp13a.1 expression amount, ameliorated WT + MO1-spint1a + MO1-st14a standard conditions Fig. 7 from Schepis et al., 2018
peridermal cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a control Fig. 5 from Armistead et al., 2020
whole organism il1b expression amount, ameliorated WT + MO1-spint1a + MO1-st14a standard conditions Fig. 7 from Schepis et al., 2018
whole organism mmp9 expression amount, ameliorated WT + MO1-spint1a + MO1-st14a standard conditions Fig. 7 from Schepis et al., 2018
epidermal basal stratum cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a control Fig. 5 from Armistead et al., 2020
peridermal cell protruding out of epidermis, exacerbated WT + MO1-spint1a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, exacerbated WT + MO1-spint1a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
caudal fin epidermal cell aggregated, exacerbated WT + MO1-spint1a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
peridermal cell protruding out of epidermis, exacerbated WT + MO1-spint1a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, exacerbated WT + MO1-spint1a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
caudal fin epidermal cell aggregated, exacerbated WT + MO1-spint1a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
caudal fin epidermal cell aggregated, ameliorated WT + MO1-spint1a + MO1-st14a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
peridermal cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a + MO2-itga3b control Fig. 5 from Armistead et al., 2020
caudal fin epidermal cell aggregated, ameliorated WT + MO1-spint1a + MO1-st14a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
epidermal basal stratum cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
peridermal cell protruding out of epidermis, ameliorated WT + MO1-spint1a + MO1-st14a + MO3-lama5 control Fig. 5 from Armistead et al., 2020
epithelial cell protruding out of epidermal superficial stratum, ameliorated cy22Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 3 with image from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-erbb2 + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated cy34Tg + MO1-erbb2 + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, abnormal cy34Tg + MO1-erbb2 + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation occurrence, ameliorated cy34Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 6 with image from Schepis et al., 2018
epidermal basal stratum cell motility occurrence, ameliorated cy34Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 6 with image from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-spint1a + MO2-mmp9 + MO3-mmp9 standard conditions Fig. 7 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, abnormal cy34Tg + MO1-spint1a + MO2-mmp9 + MO3-mmp9 chemical treatment: matrix metalloproteinase inhibitor Fig. 7 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, ameliorated f2rl1.2sfc18b/sfc18b; cy22Tg + MO1-spint1a standard conditions Fig. 3 with image from Schepis et al., 2018
epidermal basal stratum cell motility occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a standard conditions Fig. 6 with image from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell-cell junction ab2-cdh1 labeling position, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a standard conditions Fig. 5 with image from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, exacerbated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a standard conditions Fig. 6 with imageFig. 8 from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion process quality, ameliorated f2rl1.2sfc18b/sfc18b; la213Tg; mu271Tg + MO1-spint1a standard conditions Fig. 4 with image from Schepis et al., 2018
epidermal basal stratum cell motility occurrence, ameliorated f2rl1.2sfc18b/sfc18b; la213Tg; mu271Tg + MO1-spint1a standard conditions Fig. 4 with image from Schepis et al., 2018
epidermal basal stratum cell-cell adhesion process quality, ameliorated la213Tg; mu271Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 4 with image from Schepis et al., 2018
epidermal basal stratum cell motility occurrence, ameliorated la213Tg; mu271Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 4 with image from Schepis et al., 2018
epithelial cell protruding out of epidermal superficial stratum, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a standard conditions Fig. 8 from Schepis et al., 2018
epidermal superficial stratum cell population proliferation occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell population proliferation occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-erbb2 + MO1-spint1a chemical treatment: PD 168393 Fig. 8 from Schepis et al., 2018
epidermal basal stratum cell motility occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 6 with image from Schepis et al., 2018
epidermal superficial stratum cell population proliferation increased occurrence, ameliorated f2rl1.2sfc18b/sfc18b; cy34Tg + MO1-spint1a + MO1-st14a standard conditions Fig. 6 with image from Schepis et al., 2018
Citations
1 - 7 of 7
Show